The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
Male or female aged 40 to 70 years (inclusive)
Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
Treated with ocrelizumab according to routine clinical practice and at standard dose
Neurologically stable within 30 days
Diagnosis of primary progressive multiple sclerosis (PPMS) according to the revised 2017 McDonald criteria
History of clinically significant Central Nervous System disease or neurological disorders
History of confirmed Progressive Multifocal Leukoencephalopathy or neurological symptoms consistent
Active clinically significant systemic bacterial, viral, parasitic or fungal infections